Amgen, Inc. is looking to improve upon known mechanisms of action to build out its portfolio in cardiometabolic diseases beyond its LDL cholesterol-lowering biologic Repatha (evolocumab), such as with its lipoprotein(a)-lowering drug olpasiran, and full Phase II results released at the American Heart Association Scientific Sessions suggest it may be competitive with Novartis AG’s leading Lp(a) candidate pelacarsen.
Amgen’s Olpasiran Maintains Competitive Profile In Lp(a) Class
AMG 133 For Obesity Is One To Watch In CV Portfolio
The lipoprotein(a)-lowering antisense drug olpasiran reduced the cardiovascular disease risk factor Lp(a) by up to 101.1% relative to placebo. A Phase III trial will begin in December.
